Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a research note published on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

NASDAQ:ATHX opened at $0.01 on Friday. The firm has a market cap of $833,206.50, a PE ratio of -0.01 and a beta of -0.90. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.